FDA approves first artificial iris available in the U.S.

The artificial iris is made from a thin, foldable medical-grade silicone and is custom-sized and colored for individual patients. (Pixabay)

The FDA gave the green light to HumanOptics’ artificial iris, which the company says is the first standalone prosthetic device of its kind available in the U.S.

Dubbed the CustomFlex Artificial Iris, the device won premarket approval from the regulatory agency with breakthrough device designation, the agency said.

It was cleared for use in both adults and children that have a missing or damaged iris either due to a congenital condition called aniridia or as the result of being damaged. Other indications approved for the device include conditions likes albinism, traumatic injury or surgical removal due to melanoma.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye," Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices for the FDA, said in a statement. "Today's approval of the first artificial iris provides a novel method to treat iris defects that reduces sensitivity to bright light and glare. It also improves the cosmetic appearance of the eye in patients with aniridia."

The artificial iris, which is made from a thin, foldable medical-grade silicone and is custom-sized and colored for individual patients, is implanted through a small incision. The CustomFlex iris is then unfolded and smoothed using surgical instruments, and it is held in place by the anatomical structure of the eye or sutures.

Results from a clinical trial of 389 adult and pediatric patients with aniridia or other iris defects showed that 70% of patients reported significant decreases in light sensitivity and glare and improved health-related quality of life, while there was a 94% satisfaction rate among the patients with the appearance of the iris.

Suggested Articles

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.